加载中
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
前收盘价
US$7.83
−US$0.18 · -2.25%
盘中时间采用ET。市场数据可能有所延迟。
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
日内区间
当前US$7.83
52周区间
当前US$7.83
盘中时间采用ET。市场数据可能有所延迟。
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
日内区间
当前US$7.83
52周区间
当前US$7.83
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 2227.05万 USD | 2517.81万 USD | 255.15万 USD | 24.49万 USD |
| 销货成本 | — | 4996.86万 USD | 3644.8万 USD | 2181.69万 USD | — |
| 毛利 | — | −2769.81万 USD | −1127万 USD | −1926.55万 USD | 24.49万 USD |
| 研究与开发 | 8445.46万 USD | 4996.86万 USD | 3644.8万 USD | 2181.69万 USD | 1357.1万 USD |
| 销售、一般及管理费用 | 2274.86万 USD | 1486.67万 USD | 1280.79万 USD | 1043.19万 USD | 761.23万 USD |
| 营业费用 | 1.08亿 USD | 1486.67万 USD | 1280.79万 USD | 1043.19万 USD | 2118.33万 USD |
| 利息收入 | 625.76万 USD | 220.3万 USD | 172.87万 USD | 52.15万 USD | — |
| 利息支出 | 304.57万 USD | — | — | — | — |
| 折旧和摊销 | 188.9万 USD | 142.52万 USD | 106.89万 USD | 53.31万 USD | 24.57万 USD |
| 营业利润 | −1.08亿 USD | −4256.48万 USD | −2407.79万 USD | −2969.74万 USD | −2093.84万 USD |
| 净利润 | −1.05亿 USD | −4046.72万 USD | −2228.75万 USD | −2901.95万 USD | −2002.25万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$12.70
上涨空间 62.20%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2019年6月5日 | 1:10 | — | — |
股票拆分 | 2013年11月21日 | 1:50 | — | — |
股票拆分 | 2007年2月13日 | 1:10 | — | — |
已生效 2019年6月5日
1:10
已生效 2013年11月21日
1:50
已生效 2007年2月13日
1:10
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1640.47万0.00%2.3万亿 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1444.69万0.15%98.74亿 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM1146.59万0.01%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF590.67万0.01%954亿 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO395.63万0.03%139.17亿 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO306.36万0.02%180亿 USD0.06%US$112.66+0.50%
Vanguard U.S. Momentum Factor ETFVFMO205万0.10%19亿 USD0.13%US$230.11+1.02%
Vanguard Health Care ETFVHT139.62万0.01%220亿 USD0.09%US$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOVanguard U.S. Momentum Factor ETFVFMOVanguard Health Care ETFVHTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
